Project Grant R01CA297993
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$730K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $730,400 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant supports research to investigate how metabolic pathways, specifically the tricarboxylic acid (TCA) cycle, contribute to the emergence and maintenance of treatment-resistant lung adenocarcinoma (LUAD) cell states. The key objectives are to determine how TCA cycle configurations support malignant LUAD cell...
The federal Project Grant award R01CA297605, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program, supports research to develop a novel therapeutic targeting LCN2, a protein that suppresses anti-tumor immune responses, for the treatment of KRAS-driven non-small cell lung cancer (NSCLC). The $696,569 award to New York University will fund a 5-year project to: 1) characterize the impact of LCN2 on the tumor microenvironment, 2) develop...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine supports research aimed at understanding and disrupting the adeno-to-squamous transition, a mechanism by which non-small cell lung cancer can adapt and become resistant to targeted therapies like KRAS inhibitors. The $703,410 award, effective January 16, 2025 through December 31, 2029, will fund a comprehensive research program to identify specific...
This Project Grant award of $640,583 from the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program supports research by Cold Spring Harbor Laboratory (CSHL) to enhance the efficacy of immunotherapy against metastatic colorectal cancer (MCRC). The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor activity within the immunosuppressive MCRC tumor microenvironment. The research aims to delineate the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675 to The University of Texas Southwestern Medical Center to investigate the role of the Jumonji KDM4A enzyme in small cell lung cancer (SCLC). The primary goals are to determine if Jumonji inhibition can block SCLC growth, including in chemotherapy-resistant disease, by reprogramming key neuroendocrine transcription factor gene programs. The research will utilize novel...
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $689,914 Project Grant under the Cancer Treatment Research (CFDA 93.395) federal grant program to the Icahn School of Medicine at Mount Sinai. The objective of this 5-year research project is to delineate the mechanisms by which concurrent STK11 and KEAP1 gene mutations in non-small cell lung cancer (NSCLC) promote ferroptosis evasion and therapy resistance, and to establish ferroptosis as a...
This federal Project Grant award of $220,193 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to elucidate the role and mechanism of the type I interferon IFNE in KRAS-driven lung tumorigenesis. The primary awardee, Rutgers The State University of New Jersey, will use the funding to determine the intrinsic and systemic functions of IFNE in KRAS-mutant non-small cell lung cancer, including investigating whether systemic IFNE...
The National Cancer Institute (NCI) awarded a $158,365 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on the impact of NRF2 signaling activation on lung squamous cell carcinoma (LUSC) development and the tumor microenvironment. The project aims to develop a novel genetically-engineered mouse model to test how activated NRF2 affects LUSC incidence, tumor characteristics, gene/protein expression, and the...
This federal Project Grant award, totaling $678,723, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research to ascertain the pathobiological role and translational significance of non-proteolytic ubiquitination of the PD-L1 protein in evading tumoricidal T cells and improving cancer care, using lung cancer as a model. The research aims to evaluate the clinical significance of PD-L1 and an associated E3 ligase...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827.00 to New York University School of Medicine to conduct research aimed at enhancing the effectiveness of KRAS inhibitor therapy for cancer. The research project, titled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," will evaluate specific serine/threonine kinases as synthetic lethal targets to improve the response to KRAS inhibitors like...